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Background: Although high non-adherence to medication has been noticed for ulcerative colitis (UC), little is
known about adherence to mesalamine treatments and determinants that can predict adherence. The objective of
this study was to assess adherence and persistence to mesalamine treatments and their potential determinants in
mild to moderate UC patients in a real-life setting in Quebec, Canada.
Methods: A retrospective prescription and medical claims analysis was conducted using a random sample of
mesalamine users with UC. For inclusion, patients were required to initiate an oral mesalamine treatment between
January 2005 and December 2009. Patients with a diagnosis of Crohn’s disease were excluded. Treatment
adherence (medication possession ratio [MPR]) and persistence were evaluated over a 1-year period after the index
prescription using the Kaplan-Meier method with log-rank test and stepwise regression to identify potential
determinants.
Results: A sample of 1,681 of the new oral mesalamine users (mean age = 55.3) patients was obtained. Overall, the
percentage of patients with a MPR of 80% or greater at 12 months was 27.7%, while persistence was 45.5%. Among
patients treated with mesalamine delayed/extended-release tablets (MezavantW), adherence and persistence were
40.9% and 71.9%, respectively. Predictors of high adherence included, male gender (OR=1.3; 95% confidence
interval [CI]=1.1–1.6), older age (>60 years; OR=1.6; 95% CI=1.3–2.0) and current use of corticosteroids (OR=1.4; 95%
CI=1.1–1.8). Predictors of high persistence included male sex (OR=1.4; 95% CI=1.1–1.7), current use of corticosteroids
(OR=1.4; 95% CI=1.1–1.7) and presence of hypertension or respiratory diseases (OR=1.2; 95% CI=1.01–1.55).
Conclusions: The majority of patients with UC exhibited low adherence and persistence to mesalamine treatments.
Various determinants of improved adherence and persistence were identified.
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Ulcerative colitis (UC) is a ubiquitous disease, with a
worldwide incidence rate varying from 0.5 to 24.5/
100,000 persons per year [1,2]. The highest incidence
rates mainly occur in the most developed regions, no-
tably North America and Western Europe. In Canada,
the prevalence and incidence of UC are estimated as 267
cases per 100,000 and 12.9 cases per 100,000, respect-
ively [3]. In the United States, UC prevalence and* Correspondence: jean.lachaine@umontreal.ca
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reproduction in any medium, provided the orincidence rates are estimated as 214 per 100,000 and 8.8
cases per 100,000 [4]. From an European perspective, in
2000, the United Kingdom had a UC prevalence and in-
cidence rate of 153 cases per 100,000 and 19 cases per
100,000, respectively [5].
Substantial costs are associated with the management
of the disease. According to Cohen et al., the 2008 over-
all cost of UC in the European Union varied between
€12.5–29.1 billion, which comprised medical costs
(€5.4–12.6 billion) and absenteeism associated costs
(€7.1–16.5 billion) [6]. Consistent with these figures, the
economic burden associated with UC in the United
States was estimated at $US 8.1–14.9 billion in 2008.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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productivity losses were $US 4.7–6.3 billion [6].
Still incompletely understood, UC is an inflammatory
bowel disease that results from an excessive immune re-
sponse leading to intestinal inflammation [1,7]. The
course of UC over time may consist of a repeated state
of symptom exacerbation punctuated with periods of re-
mission [8]. The symptomatic relapse can be associated
with constant diarrhea, rectal bleeding, abdominal pain,
weight loss, and fatigue [9]. A Westernized environment
and lifestyle are linked to the appearance of inflamma-
tory bowel disease, which may be associated with smo-
king, diets high in fat and sugar, medication use, stress,
geographic localization and high socioeconomic status
[10]. However, their role remains uncertain and uncon-
firmed [1,7,11]. The only known risk factor associated
with UC is heredity [8,12]. Other factors, such as smo-
king status, have been associated with UC [8,11].
The American College of Gastroenterology Clinical
Practice Guidelines classify UC into 4 disease severities:
(1) mild disease, (2) moderate disease (>4 stools/day,
minimal signs of toxicity), (3) severe disease (>6 stools/
day, fever, tachycardia, anemia, elevated erythrocyte sedi-
mentation rate), and (4) fulminant disease (>10 stools/
day, continuous bleeding, toxicity, abdominal tenderness
and distension, transfusion requirement, colonic dila-
tion) [13]. Since there is no curative treatment for UC,
this inflammatory disorder is generally controlled with
pharmacological agents that are either used to control
the symptoms and/or to attenuate the inflammation.
Currently, the anti-inflammatory first line therapies for
mild to moderate UC, include olsalazine and 5-
aminosalicylic acid (5-ASA) also known as mesalamine
[14]. In Canada, the most commonly used treatments of
the active principle 5-ASA are commercialized under 4 dif-
ferent names: MezavantW, AsacolW and generics, SalofalkW,
and PentasaW [15]. Compared to the other 5-ASA treat-
ments, which need to be taken as 2 to 4 times per day,
MezavantW was designed to allow delayed and gradual
release of 5-ASA in the colon due to its Multi MatrixW
(MMXW) hydrophilic and lipophilic coating, thus it can
be taken only once daily and was shown in clinical
trails to be as effective as twice daily mesalamine for-
mulations [16,17].
In all chronic diseases, treatment adherence and per-
sistence remain significant concerns, as these conditions
may require medications to be taken for the entire or a
major part of the lifespan. Consequences of non-
adherence and persistence can be many including relap-
sing or worsening of disease, increased morbidity, or
even mortality. Indeed, Kane suggested that the major
consequences of non-adherence to 5-ASA for patients
with UC are a five-fold higher risk of relapse, an increased
risk of colorectal cancer and a reduced quality of life [18].Identification of risk factors associated with non-adherence
in UC may improve patient management and consequently
reduce relapse episodes, by providing more effective inter-
ventions intended for improving adherence. Importantly,
the lack of adherence to UC treatments has been asso-
ciated with a significant increase of costs, as non-adherent
patients who are at an increased risk of relapse are likely to
contribute to the overall high costs associated with the
treatment of UC [19].
Although high non-adherence to medication has been
reported in mild to moderate UC, little is known about
adherence to the different 5-ASA treatments and deter-
minants that can predict adherence and persistence.
Therefore, the objectives of the present study were to es-
timate adherence and persistence to 5-ASA treatments
and to identify the potential determinants of adherence
and persistence in a real-life setting.
Methods
Study database and population
A retrospective prescription claims study was conducted
using data from pharmaceutical services of the Quebec
provincial health plan database (Régie de l’assurance
maladie du Québec, RAMQ). As with other Canadian
provinces, Quebec has a universal health care program
fully subsidized by the provincial government, covering
physician services and hospitalization for the entire
population. This health care program is complemented
by a public drug plan provided to a significant propor-
tion of the population. The provincial drug reimburse-
ment program is not universal. It covers persons aged ≥65
years, beneficiaries of the social assistance program, and
individuals who do not have access to a private plan of
medication insurance. Although, the database comprises
patients from all age groups, the persons aged <65 years
are underrepresented. In 2009, approximately 3.2 million
persons (40% of the total population) were covered by the
provincial drug reimbursement program. Depending on
their incomes, some of the beneficiaries of the drug plan
co-pay or pay part of their premiums.
The RAMQ pharmaceutical services database contains
information from pharmacy claims for dispensed medi-
cations reimbursed by the program, but not for medica-
tions received in a hospital. In addition, data obtained
from the RAMQ comprise an encrypted patient identi-
fier, which enabled linkage of individual patient informa-
tion while preserving anonymity. The RAMQ data are
anonymized and are publicly available, at a cost, for re-
search purposes. The RAMQ Direction for analysis and
management of information manage the distribution of
RAMQ data to external parties.
Data on prescription claims were obtained from the
RAMQ database for the period from January 1, 2004 to
December 31, 2009 for subjects who did not have a
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tion of Diseases, Ninth Revision [ICD-9] diagnostic
codes 555.0–555.9) and who had received ≥1 of the 5-
ASA treatments during the study period. New users
(operationalized as no prescription claim in the 3
months prior to the date of the first prescription fill
[index date]) of a mesalamine treatment (AsacolW or
generics, PentasaW, SalofalkW, or MezavantW) were eli-
gible for inclusion in the analysis. Treatment adherence
(based on medication possession ratio [MPR]) and per-
sistence were evaluated over a 1-year period after the
index prescription.Data analysis
Characteristics of the study population were analyzed in
terms of age, sex, and geographical localization. Comor-
bidity level was also estimated by calculating a chronic
disease score based on the Von Korff method [20].
Number and severity of comorbidities were assessed
according to the patients’ medication profile. More spe-
cifically, occurrences of selected medication utilization
during the study period were used to calculate the
chronic disease score. Finally, the rate of predefined
most common comorbidities (heart disease, respiratory
illness, hypertension, and diabetes) was evaluated for the
entire study population.
Descriptive statistics were generated on treatment
characteristics for each 5-ASA treatment including the
number and proportion of users, the number and aver-
age duration of prescriptions, and the average quantity
of tablets per prescription.Subjects with:
Mesalamine medication from Januar
Do not have a diagnosis of Crohn’s d
Met eligible criteria 
Randomized subjects available for ana
New users 
No prescription claim in the 3 mont
prescription fill







Figure 1 Sample selection and attrition.Adherence and persistence were evaluated in new
users with no prescription claim in the 3 months prior
to the date of first prescription fill. Adherence was
defined as the consistency of medication consumption
as detailed in the recommended treatment regimen
while persistence was defined as the long-term conti-
nuation of treatment.
Adherence to treatment was estimated by calculating
the number of days for which medication was received
divided by the expected duration of the treatment
(MPR) [21]. Treatment adherence was estimated over a
1-year period [21]. The proportion of adherent patients
was estimated for each 5-ASA treatment. Patients were
considered adherent to their 5-ASA medication if their
medication possession ratio was ≥80% for a 5-ASA treat-
ment; a criterion used in other UC-adherence studies
[21,22]. As a complementary analysis, the proportion of
patients with an MPR of ≥50% was also calculated.
Treatment persistence was estimated over a 1-year
period, following the index prescription. A patient was
considered persistent for as long as the 5-ASA treatment
was not definitely ceased. Treatment cessation was
determined if the patient did not receive a 5-ASA treat-
ment for a period of ≥60 days, representing twice the
usual refill time. Patients who switched to another treat-
ment of mesalamine were considered non-persistent to
the initial medication. Time to discontinuation was cal-
culated and compared using the Kaplan-Meier method
with log-rank test.
In order to determine which factors can have an im-
pact on adherence and persistence to 5-ASA treatments,
different covariates were considered in 2 independenty 1, 2004 to December 31, 2009
isease
N = 23,530
lysis n = 12,765
hs prior to the date of the first 






Table 1 Study population
n = 1681
Age group, y, n (%)
• <20 60 (3.6)
• 20–39 287 (17.0)
• 40–59 516 (30.7)
• 60–79 734 (43.7)
• 80+ 84 (5.0)
Mean age (SD) 55.3 (17.8)
Male/Female, n (%) 729 (43.4)/952(56.6)
Rate of comorbidities, n (%)
• Hypertension 842 (50.1)
• Heart disease 695 (41.3)
• Respiratory illness 570 (33.9)
• Diabetes 549 (32.7)
SD, standard deviation.
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ities). Potential determinants for adherence and persist-
ence comprised sex, age, comorbidities, and prior or
current use of corticosteroids. Relative adherence and
persistence were estimated in consideration of each of
these potential determinants: patient age was dichoto-
mized into 2 cohorts (those <60 years and those ≥60
years); comorbidities included were heart disease, re-
spiratory illness, hypertension, and diabetes: chronic dis-
ease score was also dichotomized (those with a score
less than the median value of 6 and those with a score
of ≥6). Finally, patients who received a corticosteroid in
the year prior to the initiation of the 5-ASA treatment
were compared to those with no previous use of corti-
costeroids, as well as patients who were currently using
a corticosteroid were compared to those that were not
currently using corticosteroids. Stepwise backward re-
gression modeling was employed to identify potential
determinants for adherence and persistence from avail-
able data on the study cohort. Logistic regression ana-
lysis was performed to calculate odds ratios (ORs) and
95% confidence intervals (CIs).
For statistical analyses of comparisons between 2
groups, means of continuous variables were compared











5994 8.6 146 (102)
PentasaW (208) 1627 7.8 111.7 (92.9)
SalofalkW (817) 7317 9.0 140.0 (96.8)
MezavantW (147) 2124 14.4 77.1 (40.5)
SD, standard deviation.several groups, the F-test with one-way analysis of va-
riance (ANOVA) was conducted. Statistical analyses
were performed for comparisons between 5-ASA treat-
ments in terms of treatment characteristics, adherence
and persistence by performing the chi-square test. Statis-
tical significance was defined as P <0.05.
Results
Study sample
During the period from January 1, 2004 to December 31,
2009, a total of 23,530 patients, covered by the provin-
cial drug plan during that period, received ≥1prescrip-
tion for a mesalamine treatment. In accordance with the
RAMQ’s restrictions on the number of subjects available
for analysis by external parties, data were obtained for a
random sample of 12,765 patients. Of these, 1681 were
new users of an oral mesalamine preparation, who did
not have a diagnosis of Crohn’s disease and who were
covered by the drug plan for ≥1 year following the first
utilization of the mesalamine preparation (Figure 1). The
mean age of the study population was estimated at 55.3
years (standard deviation = 17.8), with a slightly higher
proportion of females (56.6% vs 43.4% for males). The
majority of the sample was aged between 60 to 79 years
(43.7%), while 74.4% of the sample was comprised of
patients aged between 40 to 79 years. All defined comor-
bidities (hypertension, heart disease, respiratory illness,
and diabetes) presented a high rate in this group, with
proportions ranging from 32.7% for diabetes to 50.1%
for hypertension (Table 1). The 1681 new oral 5-ASA
users received a total of 17,062 scripts for mesalamine
treatments (Table 2). The average number of scripts per
patient was 8.6 for AsacolW and generics, 7.8 for PentasaW,
9.0 for SalofalkW, and 14.4 for MezavantW. The average
duration (in days) per script was 24.0 for AsacolW and
generics, 19.8 for PentasaW, 23.0 for SalofalkW, and 27.2
for MezavantW. Based on number of scripts, SalofalkW was
the most commonly prescribed and PentasaW was the
least prescribed treatment.
Patient adherence and persistence to 5-ASA treatments
Treatment patterns with oral 5-ASA treatments were
evaluated for the study population in terms of treatment
adherence and persistence. Treatment adherence waster index date








*p<0.001 for both level of adherence (Mezavant® vs. other treatments)








Figure 2 Adherence to 5-ASA Treatments.
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ence (Figure 2). In general, treatment adherence over 12
months was relatively poor, with an overall 80% adhe-
rence to 5-ASA treatments of 27.7% and a 50% adher-
ence of 42.4%. However, adherence was significantly
higher with MezavantW users than with any other oral
treatments, with 40.9% of adherent patients compared to
ranging from 26.4% for PentasaW to 28.5% for AsacolW and
generics; P <0.001 for MezavantW versus other treatments
(Figure 2). Treatment persistence was estimated over a 1-
year period, following the index prescription. As shown in
Figure 3, treatment persistence decreased with time, al-
though the proportion of patients who were persistent du-
ring the 1-year period on MezavantW was significantly
higher when compared with those on any other 5-ASA
treatment (71.9% vs 42.8% for PentasaW to 47.5% for Asa-
colW and generics; P <0.001). Overall persistence to 5-ASA
treatments at 12 months was 45.5% (Figure 3).Figure 3 Persistence to 5-ASA treatments.Determinants of adherence and persistence
Impact of potential determinants of adherence and per-
sistence were evaluated. These include sex, age, current
or prior use of corticosteroids, as well as the impact of
having a diagnosis of another chronic disease and
chronic disease score.
Results from the regression models indicated that male
sex, older age (>60), and current use of corticosteroids
were associated with higher adherence to mesalamine
treatments (OR [95% CI] = 1.3 [1.05–1.6], 1.6 [1.3–2.0],
and 1.4 [1.1–1.8], respectively). No other covariates were
found to be associated with improved adherence. Male
sex, current use of corticosteroids, and presence of
hypertension or respiratory disease were associated with
higher persistence (OR [95% CI] = 1.4 [1.1–1.7], 1.4
[1.1–1.7], 1.2 [1.01–1.50], and 1.2 [1.004–1.548] respect-
ively; Table 3).Discussion
Our results demonstrated that, in general, adherence
and persistence observed with 5-ASA therapy in this
sample were poor. Indeed, other studies reported that
adherence to 5-ASA therapy is low, as many as 60% of
patients failing to adhere to a prescribed dose regimen
and taking <70% of their prescribed medication [23,24].
Also, for inflammatory bowel disease, treatment non-
adherence varies between 30 and 43% and was estimated
at 42% for UC patients receiving first-line therapies
[25,26]. The persistence at 12 months to 5-ASA therapy
was previously reported at 55% [27]. The poor adherence
and persistence observed can be explained by different
factors specifically related to UC and the associated
treatment regimens. Even if the 5-ASA therapy
Table 3 Impact of patients’ characteristics and comorbidities on adherence and persistence to UC treatments
Adherence Persistence
Patient’s adherent








• Male 222 (30.5) 1.3 365 (50.1) 1.4
• Female 243 (25.5) [1.05–1.6] 400 (42.0) [1.1–1.7]
Age
• < 60 201 (23.3) 1.6 381 (44.1) NS
• ≥ 60 264 (32.3) [1.3–2.0] 384 (49.9)
Previous use of corticosteroids
• Yes 142 (28.2) NS 231 (45.8) NS
• No 323 (27.4) 534 (45.4)
Concurrent use of corticosteroids
• Yes 179 (32.7) 1.4 273 (49.8) 1.4
• No 286 (25.2) [1.1–1.8] 492 (43.4) [1.1–1.7]
Heart disease
• Yes 210 (30.2) NS 321 (46.2) NS
• No 255 (25.9) 444 (45.0)
Respiratory illness
• Yes 153 (26.8) NS 247 (43.3) 1.2
• No 312 (28.1) 518 (46.6) [1.004–1.548]
Hypertension
• Yes 262 (31.1) NS 403 (47.9) 1.2
• No 203 (24.2) 362 (43.1) [1.01–1.50]
Diabetes
• Yes 167 (30.4) NS 515 (45.5) NS
• No 298 (26.3) 250 (45.5)
Chronic disease score
• Yes 159 (23.2) NS 296 (43.3) NS
• No 306 (30.7) 469 (47.0)
CI, confidence interval; NS, not significant; OR, odds ratio; UC, ulcerative colitis.
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relapses, adherence rates are particularly poor among
patients in symptomatic remission, as some of these
patients are unable to see the need for medication du-
ring the periods of symptom quiescence [24,28]. Lack of
medical supervision, concomitant medications, side
effects and cost of prescriptions were frequent reasons
for treatment non-compliance cited by patients in a
North American study [18]. However, the most cited fac-
tor was the inconvenient dosage schedule of 5-ASA
medications, which required a large number of tablets
per day. Further, in another US study of 99 patients with
quiescent UC, when asked their reasons for non-
adherence to their prescribed regimen, 30% of patients
who responded said there were too many pills, 20% did
not think they needed that much medication, and 50%said they forgot [28]. A recent study evaluating efficacy
and adherence of once daily versus 3 times daily dosing
of AsacolW showed that once daily dosing led to reduced
relapse rate, mainly due to improved adherence [3].
Consistent with these observations, we observed signifi-
cantly better adherence and persistence with MezavantW,
which is a once daily oral treatment. As 5-ASA non-
adherence is a major factor in recurrence of UC, a once
daily oral treatment with an extended drug release could
be a therapeutic option to improve adherence in UC
patients and then to maintain therapy leading to better
outcomes and to prevent relapses and complications.
This study also evaluated determinants of adherence
in terms of patient characteristics and concomitant
chronic diseases. For both adherence and persistence,
male sex was significantly associated with higher
Lachaine et al. BMC Gastroenterology 2013, 13:23 Page 7 of 8
http://www.biomedcentral.com/1471-230X/13/23adherence and higher persistence. However, contradict-
ory results have been found in the literature. A study by
Kane et al. showed that males were twice as likely as
females to be non-adherent with their UC treatment
[23]. This discrepancy in results could be due to differ-
ences in patient population for 2 studies; the Kane et al.
study was conducted with small number (n = 94) of US
patients at the University of Chicago, whereas this study
is with Canadian patients. Also patients in the Kane
et al. study were younger than patients in the current
study (51 vs. 55 years old). However, another study by
Kane et al. demonstrated that females decreased persist-
ence at 3 months [27] while Ediger et al. showed that
younger females were less adherent than older males
[29]. This latter study also reported that predictors of
adherence differed markedly between the sexes. These
results demonstrated the complexity of adherence in
UC, which seemed to differ between individuals. This
complexity was also observed in presence of concomi-
tant chronic diseases, which have a stronger impact on
adherence than persistence [30,31]. Although some of
the covariates in our study have a significant impact on
adherence and persistence, this impact is somewhat li-
mited with ORs of 1.2 to 1.6.
As this study was performed using data from an ad-
ministrative claims database, it enables the inclusion of a
large number of subjects that are assumed to accurately
represent the general population of Quebec province of
Canada and in a real-world clinical setting, contrary to a
clinical trial, with relatively small sample size and con-
trolled clinical environment. Specifically in contrast to
this study, clinical trials reported excellent rates of ad-
herence with 5-ASA therapy, in the order of 80% of
patients or more [32,33]. As participants are generally
better motivated and under close medical supervision
compared with those receiving therapy outside the cli-
nical trial setting, these rates do not necessarily reflect
real-world use and from this point of view, the RAMQ
database allows a more accurate estimation of adherence
and persistence. However, as in other studies based on
administrative databases, there are some inherent limita-
tions. It is assumed that reimbursed medications
retrieved from the databases were taken by the patient,
although this may not be always the case. Also, drug
samples received by the patient from his/her physician,
medications received while hospitalized and medication
not reimbursed by the drug plan, including over-the-
counter medications, are not taken into account. Ano-
ther limitation of this study was the relatively older age
of the patient population who were covered under a free
drug prescription benefit. Moreover, the presence of a
claim for a filled prescription does not necessarily indi-
cate that the medication was consumed or that it was
taken as prescribed, which can potentially affectadherence results. Furthermore, some patients with UC
may have been excluded if they also carry a diagnosis of
CD. Also, some patients with CD may have been kept if
they were never given a CD diagnosis. This limitation is
inherent to this kind of database, but is also a reflection
of the difficulties of distinguishing betwenn these two
diagnoses in clinical practice. Neverthess, this would have
had a limited impact on the relative adherence and per-
sistence of one medication compared to another.Conclusions
In summary, this RAMQ-based analysis provides de-
scriptive information regarding prescription characteris-
tics and 5-ASA adherence and persistence. The overall
findings demonstrated that, in a real-life setting, adher-
ence and persistence were poor in 5-ASA patients, al-
though it was improved with MezavantW, suggesting that
once daily treatments could help to improve adherence
and persistence of 5-ASA patients and may lead to a de-
crease in frequency of UC exacerbations. Reasons for ad-
herence and persistence to 5-ASA treatments are
complex and vary from 1 patient to another. Better
understanding of determinants may improve UC ma-
nagement by providing strategies to improve adherence
and persistence and thereby reducing relapses.
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